Epidermolysis bullosa simplex, Dowling-Meara type

From WikiMD's WELLNESSPEDIA

Alternate names[edit]

EBS-DM; Dowling-Meara type epidermolysis bullosa simplex; Epidermolysis bullosa herpetiformis, Dowling-Meara type; Epidermolysis bullosa simplex, herpetiformis

Definition[edit]

Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM) is a basal subtype of epidermolysis bullosa simplex (EBS) characterized by the presence of generalized vesicles and small blisters in grouped or arcuate configuration.

Epidemiology[edit]

Worldwide prevalence is unknown but reported prevalence in Scotland is 1/1,700,000.

Cause[edit]

EBS-DM is caused by dominant negative mutations within either the KRT5 (12q13.13) or KRT14 (17q12-q21) genes, encoding keratin 5 and keratin 14, respectively.

Inheritance[edit]

Autosomal dominant pattern, a 50/50 chance.

Transmission is autosomal dominant and sporadic cases are frequent.

Onset[edit]

Onset is usually at birth with large, frequently hemorrhagic blisters.

Signs and symptoms[edit]

  • After the neonatal period, the lesions take the typical herpetiform (or herpes-like) clustering with central healing pattern.
  • Blister formation gradually reduces starting from late childhood.
  • By childhood, most patients begin to develop confluent thickening and hyperkeratosis (keratoderma) of the palms and soles which may partially resolve in some patients during mid- to late-adulthood.
  • Along with blisters, skin findings commonly include mild atrophic scarring and post-inflammatory pigmentation, nail shedding and nail dystrophy, as well as occasional milia formation.
  • Lesions may improve in some patients in case of fever, unlike other forms of EB in which warmer weather exacerbates disease activity. The reason for this is unknown.
  • Extracutaneous complications can occur including oral cavity blistering, constipation and, rarely, tracheolaryngeal compromise.

Diagnosis[edit]

The diagnosis of epidermolysis bullosa simplex (EBS) is established in a proband by the identification of heterozygous (or rarely biallelic) pathogenic variants in KRT5 or KRT14 by molecular genetic testing; examination of a skin biopsy using immunofluorescence microscopy and transmission electron microscopy may be considered but can have limitations in the diagnosis of EBS.[1][1].

Treatment[edit]

  • Supportive care to protect the skin from blistering; use of dressings that will not further damage the skin and will promote healing of open wounds.
  • Lance and drain new blisters.
  • Dressings involve three layers: a primary nonadherent contact layer; a secondary layer providing stability, adding padding, and absorbing drainage; and a tertiary layer with elastic properties.[2][2].

References[edit]

  1. Pfendner EG, Bruckner AL. Epidermolysis Bullosa Simplex. 1998 Oct 7 [Updated 2016 Oct 13]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1369/
  2. Pfendner EG, Bruckner AL. Epidermolysis Bullosa Simplex. 1998 Oct 7 [Updated 2016 Oct 13]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1369/




NIH genetic and rare disease info[edit]

Epidermolysis bullosa simplex, Dowling-Meara type is a rare disease.